Helix Biopharma (OTCMKTS:HBPCF – Get Free Report) is expected to announce its resultson Thursday, October 29th. Analysts expect Helix Biopharma to post earnings of ($0.0813) per share for the quarter.
Helix Biopharma Stock Performance
Shares of OTCMKTS:HBPCF opened at $0.77 on Thursday. Helix Biopharma has a 52-week low of $0.77 and a 52-week high of $1.73. The company has a 50-day simple moving average of $1.37 and a 200 day simple moving average of $1.59.
Helix Biopharma Company Profile
Helix BioPharma Corp. is a Canadian clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. Its research has centered on treatments designed to address solid tumors and the tumor microenvironment.
The company’s lead investigational product is L-DOS47, an antibody-enzyme conjugate designed to target CEACAM6, a protein expressed on certain cancer cells. L-DOS47 combines a humanized monoclonal antibody with a urease enzyme intended to convert urea into ammonia near targeted tumor cells, potentially altering the tumor environment and enhancing anticancer activity.
Featured Stories
- Five stocks we like better than Helix Biopharma
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
Receive News & Ratings for Helix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
